New Strategies for Overcoming Limitations of Mesenchymal Stem Cell-Based Immune Modulation.
10.15283/ijsc.2015.8.1.54
- Author:
Nayoun KIM
1
;
Seok Goo CHO
Author Information
1. Institute for Translational Research and Molecular Imaging, The Catholic University of Korea College of Medicine, Seoul, Korea. chosg@catholic.ac.kr
- Publication Type:Clinical Trial ; Review
- Keywords:
Mesenchymal stem cells;
Immune modulation;
Clinical trial;
Limitation
- MeSH:
Graft vs Host Disease;
Hope;
Mesenchymal Stromal Cells
- From:International Journal of Stem Cells
2015;8(1):54-68
- CountryRepublic of Korea
- Language:English
-
Abstract:
Mesenchymal stem cells (MSCs) have rapidly been applied in a broad field of immune-mediated disorders since the first successful clinical use of MSCs for treatment of graft-versus-host disease. Despite the lack of supporting data, expectations that MSCs could potentially treat most inflammatory conditions led to rushed application and development of commercialized products. Today, both pre-clinical and clinical studies present mixed results for MSC therapy and the discrepancy between expected and actual efficacy of MSCs in various diseases has evoked a sense of discouragement. Therefore, we believe that MSC therapy may now be at a critical milestone for re-evaluation and re-consideration. In this review, we summarize the current status of MSC-based clinical trials and focus on the discrepancy between expected and actual outcome of MSC therapy from bench to bedside. Importantly, we discuss the underlying limitations of MSCs and suggest a new guideline for MSC therapy in hopes of improving their therapeutic efficacy.
